The goal of this study was to test the validity of the machine learning approach and the ability of the [18F]PM‐PBB3 tracer to identify and characterize tau pathology in two distinct neurodegenerative disorders: namely, AD (3R + 4R tauopathy) and PSP (4R tauopathy). Here, MAPT is linked to supranuclear palsy, progressive, 1.